⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
businesswire.com
IONS
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
IONS
PFE
REGN
LXRX
VRTX
LLY
$15.5 Bn Next Generation Drug Conjugates Market Trends and Global Forecasts, 2035
globenewswire.com
ALNY
ARWR
GERN
IONS
n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases USA - English USA - English USA - Français USA - Deutsch
prnewswire.com
IONS
n-Lorem and EspeRare annoncent une collaboration européenne pour élargir l'accès aux thérapies ASO individualisées pour les maladies génétiques rares USA - Français USA - English USA - Deutsch
prnewswire.com
IONS
n-Lorem und EspeRare kündigen europäische Zusammenarbeit zur Erweiterung des Zugangs zu individualisierten ASO-Therapien für seltene genetische Erkrankungen an USA - Deutsch USA - English USA - Français
prnewswire.com
IONS
n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
prnewswire.com
IONS
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight
globenewswire.com
AMGN
ARWR
IONS
NVS
NVO
MRK
LLY
REGN
ESPR
ALNY
VRTX
XBI
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
globenewswire.com
BIIB
IONS
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
businesswire.com
IONS